deaths (OS)progression or deaths (PFS)RFS/DFS

metastatic/advanced RCC (mRCC) - 2nd line (L2) metastatic/advanced RCC (mRCC) - 2nd line (L2)

versus everolimus
nivolumab alone vs. everolimus 1 certainty unassessablestatistically conclusive-25% certainty unassessable-11%-